Literature DB >> 17218411

Development of l-CDB-4022 as a nonsteroidal male oral contraceptive: induction and recovery from severe oligospermia in the adult male cynomolgus monkey (Macaca fascicularis).

Sheri Ann Hild1, Gary R Marshall, Barbara J Attardi, Rex A Hess, Stefan Schlatt, David R Simorangkir, Suresh Ramaswamy, Sailaja Koduri, Jerry R Reel, Tony M Plant.   

Abstract

The present study was undertaken to examine the antispermatogenic effect of l-CDB-4022 in the adult male cynomolgus monkey. Monkeys (four per group) were dosed via nasogastric tube for 7 d with l-CDB-4022 at 12.5 mg/kg.d or vehicle (d 0=first day of dosing). Plasma levels of l-CDB-4022 and its deesterified metabolite were nondetectable prior to treatment and in all vehicle-treated monkeys. Peak levels of l-CDB-4022 and its metabolite were observed at 4 h after dosing with steady-state levels apparent around d 4. Sperm concentration and total sperm per ejaculate were decreased to levels below 1x10(6) sperm/ml or sperm/ejaculate in l-CDB-4022-treated monkeys by d 17 and remained suppressed through wk 6. Sperm motility also declined to 0% for 6 wk. Testicular volume was reduced in l-CDB-4022-treated monkeys through d 21. The left testis and epididymis were removed from all monkeys on d 24. At this time, the most mature germ cells in the seminiferous tubules of testes from l-CDB-4022-treated monkeys were either spermatocytes or round spermatids. Immature germ cells, but not mature sperm, were found in the efferent ducts and collapsed epididymal lumen of l-CDB-4022-treated monkeys. A steady recovery in sperm motility, concentration, and total sperm per ejaculate was observed in l-CDB-4022-treated monkeys such that these parameters were not different from those of vehicle-treated monkeys by wk 16. Volume of the remaining testis increased in vehicle- and l-CDB-4022-treated monkeys after hemicastration; however, the increase in l-CDB-4022-treated monkeys was delayed compared with that observed in the vehicle-treated monkeys. The morphology of the remaining testis and epididymis, which were removed on wk 17, was normal. Serum inhibin B levels were increased in l-CDB-4022-treated monkeys during the dosing interval; thereafter serum inhibin B levels declined such that there was no difference between the groups by wk 3. l-CDB-4022 treatment did not affect circulating levels of testosterone, LH, FSH, or estradiol. In conclusion, these data indicate that in the cynomolgus monkey, a representative higher primate, l-CDB-4022 exerts a selective antispermatogenic action, which was reversible under the conditions of this study and thus has potential as a nonhormonal oral male contraceptive.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17218411     DOI: 10.1210/en.2006-1487

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  17 in total

Review 1.  Delivering non-hormonal contraceptives to men: advances and obstacles.

Authors:  Dolores D Mruk; C Yan Cheng
Journal:  Trends Biotechnol       Date:  2008-01-11       Impact factor: 19.536

Review 2.  Anchoring junctions as drug targets: role in contraceptive development.

Authors:  Dolores D Mruk; Bruno Silvestrini; C Yan Cheng
Journal:  Pharmacol Rev       Date:  2008-05-15       Impact factor: 25.468

Review 3.  The blood-testis barrier and its implications for male contraception.

Authors:  C Yan Cheng; Dolores D Mruk
Journal:  Pharmacol Rev       Date:  2011-10-28       Impact factor: 25.468

Review 4.  Regulation of blood-testis barrier by actin binding proteins and protein kinases.

Authors:  Nan Li; Elizabeth I Tang; C Yan Cheng
Journal:  Reproduction       Date:  2015-12-01       Impact factor: 3.906

5.  Single, escalating dose pharmacokinetics, safety and food effects of a new oral androgen dimethandrolone undecanoate in man: a prototype oral male hormonal contraceptive.

Authors:  Prasanth Surampudi; Stephanie T Page; Ronald S Swerdloff; Jean Jacques Nya-Ngatchou; Peter Y Liu; John K Amory; Andrew Leung; Laura Hull; Diana L Blithe; Jason Woo; William J Bremner; Christina Wang
Journal:  Andrology       Date:  2014-05-02       Impact factor: 3.842

Review 6.  New frontiers in nonhormonal male contraception.

Authors:  C Yan Cheng; Dolores D Mruk
Journal:  Contraception       Date:  2010-05-06       Impact factor: 3.375

Review 7.  Pipeline for contraceptive development.

Authors:  Diana L Blithe
Journal:  Fertil Steril       Date:  2016-08-11       Impact factor: 7.329

8.  Mechanism of action of l-CDB-4022, a potential nonhormonal male contraceptive, in the seminiferous epithelium of the rat testis.

Authors:  Sailaja Koduri; Sheri Ann Hild; Laurent Pessaint; Jerry R Reel; Barbara J Attardi
Journal:  Endocrinology       Date:  2008-01-03       Impact factor: 4.736

Review 9.  Advances in male contraception.

Authors:  Stephanie T Page; John K Amory; William J Bremner
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

10.  Effects of 28 Days of Oral Dimethandrolone Undecanoate in Healthy Men: A Prototype Male Pill.

Authors:  Arthi Thirumalai; Jonas Ceponis; John K Amory; Ronald Swerdloff; Vijaya Surampudi; Peter Y Liu; William J Bremner; Eric Harvey; Diana L Blithe; Min S Lee; Laura Hull; Christina Wang; Stephanie T Page
Journal:  J Clin Endocrinol Metab       Date:  2019-02-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.